16 Jan
  • By leilanifera
  • Cause in

CureDuchenne to Host Webinar with TRiNDS on a New Solution for the Duchenne Research Community

NEWPORT BEACH, Calif., January 16, 2017 –  CureDuchenne, a nonprofit dedicated to funding research and improving patient care for Duchenne muscular dystrophy, will host a webinar with TRiNDS, a new specialized contract research organization for neuromuscular diseases, on January 24 at 1 p.m. EST/10 a.m. PST. The webinar is an opportunity for the Duchenne community […]

READ MORE
10 Jan
  • By L Fera
  • Cause in

BioMarin Transfers Duchenne Natural History Database to CureDuchenne To Improve Knowledge of Duchenne Patients and Improve Clinical Outcomes

NEWPORT BEACH, Calif., January 10, 2017 –  CureDuchenne announced today that BioMarinPharmaceutical Inc. has transferred its Duchenne natural history database to CureDuchenne, the venture philanthropy not-for-profit organization that is leading Duchenne research. CureDuchenne will house and maintain BioMarin’s natural history database, and will facilitate sharing of currently warehoused data and collaborate with other institutions as well, […]

READ MORE
19 Dec
  • By L Fera
  • Cause in

CureDuchenne Ventures Invests in TRiNDS to Provide Clinical Trial Solutions for Neuromuscular Disorders

NEWPORT BEACH, Calif., Dec. 19, 2016 –  CureDuchenne Ventures, LLC, a company that funds research to find a cure for Duchenne muscular dystrophy, announced today that they invested inTRiNDS, LLC, a new contract research organization born from the Cooperative International Neuromuscular Research Group (CINRG) academic consortium. Therapeutic Research in Neuromuscular Disorders Solutions (TRiNDS) provides specialized […]

READ MORE
28 Nov
  • By L Fera
  • Cause in

CureDuchenne Aims for a Treatment for the 87%

Newport Beach, CA Nov. 28, 2016 — It has taken decades, millions of research dollars, heartache and hopefulness to reach a critical milestone of the first FDA approved pharmaceutical treatment for those with Duchenne muscular dystrophy. This first treatment will only help 13% of those who battle with this genetic disease, and CureDuchenne, a national […]

READ MORE
25 Oct
  • By leilanifera
  • Cause in

CureDuchenne To Host Webinar With Marathon Pharmaceuticals on November 1 to Update the Duchenne Community on Deflazacort Access and Regulatory Status

NEWPORT BEACH, CA. October 25, 2016 – CureDuchenne, a nonprofit dedicated to funding research and improving patient care for Duchenne muscular dystrophy, will host an informational webinar on November 1, 2016 at 2:00 p.m. ET/11:00 a.m. PT to update the community on Marathon Pharmaceutical’s efforts to secure FDA approval for deflazacort. If deflazacort is approved […]

READ MORE
25 Oct
  • By L Fera
  • Cause in

Nonprofits, Pharmaceutical Companies and Noted Clinicians Join to Launch the Collaborative Trajectory Analysis Project (cTAP), Advancing Clinical Trial Design for Duchenne Muscular Dystrophy

Consortium Working Together to Bring Quality of Life Treatments to the Duchenne Community NEWPORT BEACH, Calif., October 25, 2016 – The next wave in tackling Duchenne Muscular Dystrophy is getting a boost from a collaboration of nonprofit organizations, biopharmaceutical companies and noted clinicians who have joined together to advance the progress of drug development and […]

READ MORE
07 Oct
  • By leilanifera
  • Cause in

CureDuchenne to Host a Webinar on Duplication Research for Duchenne with Dr. Flanigan From Nationwide Children’s Hospital on October 12

NEWPORT BEACH, Calif., October 7, 2016: CureDuchenne, a nonprofit dedicated to funding research and improving patient care for Duchenne muscular dystrophy, will host a webinar with Dr. Kevin Flanigan from Nationwide Children’s Hospital on October 12 at 4 p.m. ET/ 1 p.m. PT. The webinar is an opportunity for the Duchenne community to learn the […]

READ MORE
06 Oct
  • By L Fera
  • Cause in

CureDuchenne To Host SareptAssist Webinar on October 11 to Provide an Overview of Sarepta’s Patient Support Program for Duchenne Families

NEWPORT BEACH, CA. October 6, 2016 – CureDuchenne, a nonprofit dedicated to funding research and improving patient care for Duchenne muscular dystrophy, will host a webinar with Sarepta Therapeutics, Inc. (NASDAQ: SRPT) on October 11 at 1 p.m. ET/10 a.m. PT to provide the Duchenne community an overview of Sarepta’s patient support program, SareptAssist. The […]

READ MORE